FBRX
Forte Biosciences, Inc.
Price Chart
Latest Quote
$18.28
+0.43 (+2.41%)
Current Price
| Previous Close | $17.85 |
| Open | $17.94 |
| Day High | $19.01 |
| Day Low | $17.77 |
| Volume | 227,627 |
Stock Information
| Shares Outstanding | 20.48M |
| Cash Equivalents | $58.22M |
| Net Income | $-75.86M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $374.35M |
| EPS (TTM) | $-4.59 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $377.95M |
| Income | $-75.86M |
| Book/sh | $2.36 |
| Cash/sh | $2.84 |
| Employees | 22 |
Financial Ratios
| Quick Ratio | 2.49 |
| Current Ratio | 2.75 |
Returns & Margins
| ROA | -83.90% |
| ROE | -188.40% |
Ownership
| Insider Ownership | 2.15% |
| Institutional Ownership | 74.84% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -4.41 |
| P/B | 7.76 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $63.75 |
Technical Indicators
| SMA20 | $18.29 |
| SMA50 | $23.76 |
| SMA200 | $22.36 |
| RSI | 44.24 |
| ATR | 1.2964 |
| Shares Float | 18.83M |
| Short Float | 6.72% |
| Short Ratio | 6.16 |
| Volatility | 2.87 |
| Rel Volume | 0.91 |
Performance History
| Week | +4.10% |
| Month | -10.00% |
| Quarter | -22.21% |
| 6 Months | -26.14% |
| YTD | -22.58% |
| Year | +46.89% |
| 3 Years | -29.01% |
| 5 Years | -98.20% |
| 10 Years | -99.61% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-22 | $18.28 | 227,627 |
| 2026-06-18 | $17.85 | 228,700 |
| 2026-06-17 | $17.59 | 156,100 |
| 2026-06-16 | $17.15 | 186,300 |
| 2026-06-15 | $18.05 | 125,000 |
| 2026-06-12 | $17.56 | 219,300 |
| 2026-06-11 | $17.40 | 172,200 |
| 2026-06-10 | $16.82 | 254,600 |
| 2026-06-09 | $17.00 | 415,500 |
| 2026-06-08 | $15.67 | 248,800 |
| 2026-06-05 | $16.52 | 408,700 |
| 2026-06-04 | $16.69 | 283,900 |
| 2026-06-03 | $17.00 | 354,600 |
| 2026-06-02 | $18.17 | 367,600 |
| 2026-06-01 | $19.24 | 354,800 |
| 2026-05-29 | $19.07 | 392,800 |
| 2026-05-28 | $20.77 | 144,900 |
| 2026-05-27 | $21.47 | 126,400 |
| 2026-05-26 | $21.94 | 205,100 |
About Forte Biosciences, Inc.
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's lead product candidate is the FB-102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for various autoimmune and autoimmune-related indications, such as celiac disease, vitiligo, alopecia areata, and type 1 diabetes. Forte Biosciences, Inc. is headquartered in Dallas, Texas.
đ° Latest News
One Forte Biosciences Insider Raised Stake By 30% In Previous Year
Simply Wall St. âĸ 2026-06-13T13:24:43Z
Top Midday Gainers
MT Newswires âĸ 2026-04-09T18:05:10ZForte Biosciences (FBRX) Upgraded to Buy: Here's What You Should Know
Zacks âĸ 2026-02-25T17:00:03Z
We Think Forte Biosciences (NASDAQ:FBRX) Can Afford To Drive Business Growth
Simply Wall St. âĸ 2026-02-18T11:22:04Z
Chief Financial Officer of Forte Biosciences Picks Up 30% More Stock
Simply Wall St. âĸ 2026-01-04T12:32:08Z
Positive week for Forte Biosciences, Inc. (NASDAQ:FBRX) institutional investors who lost 1.7% over the past year
Simply Wall St. âĸ 2025-12-12T13:02:40Z
We're Hopeful That Forte Biosciences (NASDAQ:FBRX) Will Use Its Cash Wisely
Simply Wall St. âĸ 2025-09-11T11:13:40Z
This Forte Biosciences Insider Increased Their Holding By 273% Last Year
Simply Wall St. âĸ 2025-08-15T10:11:18Z
individual investors who own 54% along with institutions invested in Forte Biosciences, Inc. (NASDAQ:FBRX) saw increase in their holdings value last week
Simply Wall St. âĸ 2025-07-05T12:09:40Z
Top Midday Decliners
MT Newswires âĸ 2025-06-25T18:44:36Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $70,657,000 | $36,602,000 | $32,486,000 | $13,896,000 |
| Other Income Expense | $-396,000 | $-190,000 | $-114,000 | $-145,000 |
| Other Non Operating Income Expenses | $-396,000 | $-190,000 | $-114,000 | $-145,000 |
| Net Non Operating Interest Income Expense | $2,715,000 | $1,314,000 | $1,124,000 | $162,000 |
| Operating Expense | $70,657,000 | $36,602,000 | $32,486,000 | $13,896,000 |
| General And Administrative Expense | $12,410,000 | $15,409,000 | $10,624,000 | $8,302,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-69,375,000 | $-35,478,000 | $-31,476,000 | $-13,879,000 |
| Net Interest Income | $2,715,000 | $1,314,000 | $1,124,000 | $162,000 |
| Interest Income | $2,715,000 | $1,314,000 | $1,124,000 | $162,000 |
| Normalized Income | $-69,375,000 | $-35,478,000 | $-31,476,000 | $-13,879,000 |
| Net Income From Continuing And Discontinued Operation | $-69,375,000 | $-35,478,000 | $-31,476,000 | $-13,879,000 |
| Total Operating Income As Reported | $-70,657,000 | $-36,602,000 | $-32,486,000 | $-13,896,000 |
| Net Income Common Stockholders | $-69,375,000 | $-35,478,000 | $-31,476,000 | $-13,879,000 |
| Net Income | $-69,375,000 | $-35,478,000 | $-31,476,000 | $-13,879,000 |
| Net Income Including Noncontrolling Interests | $-69,375,000 | $-35,478,000 | $-31,476,000 | $-13,879,000 |
| Net Income Continuous Operations | $-69,375,000 | $-35,478,000 | $-31,476,000 | $-13,879,000 |
| Pretax Income | $-68,338,000 | $-35,478,000 | $-31,476,000 | $-13,879,000 |
| Interest Income Non Operating | $2,715,000 | $1,314,000 | $1,124,000 | $162,000 |
| Operating Income | $-70,657,000 | $-36,602,000 | $-32,486,000 | $-13,896,000 |
| Special Income Charges | - | - | - | - |
| Per Share | ||||
| Diluted EPS | $-4.71 | $-12.17 | $-24.92 | $-20.00 |
| Basic EPS | $-4.71 | $-12.17 | $-24.92 | $-20.00 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-70,593,000 | $-36,563,000 | $-32,477,000 | $-13,896,000 |
| Reconciled Depreciation | $64,000 | $39,000 | $9,000 | $0 |
| EBITDA (Bullshit earnings) | $-70,593,000 | $-36,563,000 | $-32,477,000 | $-13,896,000 |
| EBIT | $-70,657,000 | $-36,602,000 | $-32,486,000 | $-13,896,000 |
| Diluted Average Shares | $14,717,734 | $2,915,894 | $1,262,840 | $695,341 |
| Basic Average Shares | $14,717,734 | $2,915,894 | $1,262,840 | $695,341 |
| Diluted NI Availto Com Stockholders | $-69,375,000 | $-35,478,000 | $-31,476,000 | $-13,879,000 |
| Tax Provision | $1,037,000 | - | - | - |
| Research And Development | $58,247,000 | $21,193,000 | $21,862,000 | $5,594,000 |
| Selling General And Administration | $12,410,000 | $15,409,000 | $10,624,000 | $8,302,000 |
| Other Gand A | $12,410,000 | $15,409,000 | $10,624,000 | $8,302,000 |
| Total Unusual Items | - | - | - | - |
| Total Unusual Items Excluding Goodwill | - | - | - | - |
Fetched: 2026-06-18
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $60,991,000 | $52,480,000 | $35,314,000 | $38,818,000 |
| Total Assets | $82,779,000 | $61,561,000 | $38,980,000 | $41,997,000 |
| Total Non Current Assets | $2,190,000 | $215,000 | $653,000 | $486,000 |
| Other Non Current Assets | $25,000 | $26,000 | $53,000 | $13,000 |
| Non Current Prepaid Assets | $2,036,000 | $112,000 | $491,000 | $473,000 |
| Current Assets | $80,589,000 | $61,346,000 | $38,327,000 | $41,511,000 |
| Other Current Assets | $422,000 | $208,000 | $165,000 | $70,000 |
| Prepaid Assets | $2,393,000 | $2,645,000 | $1,037,000 | $341,000 |
| Receivables | $817,000 | $128,000 | - | - |
| Taxes Receivable | $817,000 | $128,000 | - | - |
| Cash Cash Equivalents And Short Term Investments | $76,957,000 | $58,365,000 | $37,125,000 | $41,100,000 |
| Cash And Cash Equivalents | $76,957,000 | $22,244,000 | $11,961,000 | $41,100,000 |
| Cash Equivalents | $73,677,000 | $20,780,000 | $5,686,000 | $5,061,000 |
| Cash Financial | $3,280,000 | $1,464,000 | $6,275,000 | $36,039,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $21,788,000 | $9,081,000 | $3,666,000 | $3,179,000 |
| Total Non Current Liabilities Net Minority Interest | $1,037,000 | $0 | $0 | $0 |
| Tradeand Other Payables Non Current | $1,037,000 | $0 | - | - |
| Current Liabilities | $20,751,000 | $9,081,000 | $3,666,000 | $3,179,000 |
| Payables And Accrued Expenses | $18,501,000 | $7,530,000 | $2,719,000 | $2,289,000 |
| Payables | $9,989,000 | $4,879,000 | $1,424,000 | $1,153,000 |
| Accounts Payable | $9,989,000 | $4,879,000 | $1,424,000 | $1,153,000 |
| Equity | ||||
| Common Stock Equity | $60,991,000 | $52,480,000 | $35,314,000 | $38,818,000 |
| Total Equity Gross Minority Interest | $60,991,000 | $52,480,000 | $35,314,000 | $38,818,000 |
| Stockholders Equity | $60,991,000 | $52,480,000 | $35,314,000 | $38,818,000 |
| Gains Losses Not Affecting Retained Earnings | $3,000 | $11,000 | $4,000 | $0 |
| Other Equity Adjustments | $3,000 | $11,000 | $4,000 | - |
| Retained Earnings | $-223,373,000 | $-153,998,000 | $-118,520,000 | $-87,044,000 |
| Preferred Securities Outside Stock Equity | - | - | - | - |
| Other | ||||
| Ordinary Shares Number | $12,948,308 | $6,393,323 | $1,453,404 | $840,002 |
| Share Issued | $12,948,308 | $6,393,323 | $1,453,404 | $840,002 |
| Tangible Book Value | $60,991,000 | $52,480,000 | $35,314,000 | $38,818,000 |
| Invested Capital | $60,991,000 | $52,480,000 | $35,314,000 | $38,818,000 |
| Working Capital | $59,838,000 | $52,265,000 | $34,661,000 | $38,332,000 |
| Total Capitalization | $60,991,000 | $52,480,000 | $35,314,000 | $38,818,000 |
| Additional Paid In Capital | $284,348,000 | $206,461,000 | $153,829,000 | $125,841,000 |
| Capital Stock | $13,000 | $6,000 | $1,000 | $21,000 |
| Common Stock | $13,000 | $6,000 | $1,000 | $21,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $2,250,000 | $1,551,000 | $947,000 | $890,000 |
| Current Accrued Expenses | $8,512,000 | $2,651,000 | $1,295,000 | $1,136,000 |
| Net PPE | $129,000 | $77,000 | $109,000 | $0 |
| Accumulated Depreciation | $-112,000 | $-48,000 | $-9,000 | $0 |
| Gross PPE | $241,000 | $125,000 | $118,000 | $0 |
| Other Properties | $223,000 | $107,000 | $100,000 | - |
| Machinery Furniture Equipment | $18,000 | $18,000 | $18,000 | $0 |
| Other Short Term Investments | $0 | $36,121,000 | $25,164,000 | - |
| Treasury Shares Number | - | - | $0 | - |
Fetched: 2026-06-18
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-50,998,000 | $-30,782,000 | $-28,794,000 | $-8,185,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-50,882,000 | $-30,745,000 | $-28,706,000 | $-8,185,000 |
| Cash Flow From Continuing Operating Activities | $-50,882,000 | $-30,745,000 | $-28,706,000 | $-8,185,000 |
| Investing Activities | ||||
| Capital Expenditure | $-116,000 | $-37,000 | $-88,000 | - |
| Investing Cash Flow | $36,234,000 | $-35,993,000 | $47,000 | $0 |
| Cash Flow From Continuing Investing Activities | $36,234,000 | $-35,993,000 | $47,000 | $0 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $0 | $-1,000 | $0 | - |
| Issuance Of Capital Stock | $75,000,000 | $53,000,000 | $25,000,000 | $7,229,000 |
| Financing Cash Flow | $69,361,000 | $51,857,000 | $24,684,000 | $7,241,000 |
| Cash Flow From Continuing Financing Activities | $69,361,000 | $51,857,000 | $24,684,000 | $7,241,000 |
| Net Other Financing Charges | $-7,470,000 | $-1,156,000 | $-332,000 | - |
| Net Common Stock Issuance | $75,000,000 | $52,999,000 | $25,000,000 | $7,229,000 |
| Common Stock Issuance | $75,000,000 | $53,000,000 | $25,000,000 | $7,229,000 |
| Other | ||||
| End Cash Position | $76,957,000 | $22,244,000 | $37,125,000 | $41,100,000 |
| Beginning Cash Position | $22,244,000 | $37,125,000 | $41,100,000 | $42,044,000 |
| Changes In Cash | $54,713,000 | $-14,881,000 | $-3,975,000 | $-944,000 |
| Proceeds From Stock Option Exercised | $1,831,000 | $14,000 | $16,000 | $12,000 |
| Common Stock Payments | $0 | $-1,000 | $0 | - |
| Net Investment Purchase And Sale | $36,350,000 | $-35,956,000 | $135,000 | $0 |
| Sale Of Investment | $36,350,000 | $0 | $10,100,000 | $0 |
| Purchase Of Investment | $0 | $-35,956,000 | $-9,965,000 | $0 |
| Net PPE Purchase And Sale | $-116,000 | $-37,000 | $-88,000 | $0 |
| Purchase Of PPE | $-116,000 | $-37,000 | $-88,000 | $0 |
| Change In Working Capital | $11,371,000 | $1,757,000 | $-392,000 | $1,679,000 |
| Change In Payables And Accrued Expense | $13,945,000 | $3,130,000 | $457,000 | $1,421,000 |
| Change In Accrued Expense | $8,402,000 | $109,000 | $186,000 | $1,214,000 |
| Change In Payable | $5,543,000 | $3,021,000 | $271,000 | $207,000 |
| Change In Account Payable | $5,543,000 | $3,021,000 | $271,000 | $207,000 |
| Change In Prepaid Assets | $-2,574,000 | $-1,373,000 | $-849,000 | $258,000 |
| Other Non Cash Items | $-237,000 | $-158,000 | $-131,000 | - |
| Stock Based Compensation | $6,258,000 | $3,095,000 | $3,284,000 | $4,015,000 |
| Deferred Tax | $1,037,000 | $0 | - | - |
| Deferred Income Tax | $1,037,000 | $0 | - | - |
| Depreciation Amortization Depletion | $64,000 | $39,000 | $9,000 | $0 |
| Depreciation And Amortization | $64,000 | $39,000 | $9,000 | $0 |
| Depreciation | $64,000 | $39,000 | $9,000 | $0 |
| Net Income From Continuing Operations | $-69,375,000 | $-35,478,000 | $-31,476,000 | $-13,879,000 |
| Asset Impairment Charge | - | - | - | $0 |
Fetched: 2026-06-18